alpha 2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis

Systemic sclerosis is a connective tissue disease of unknown origin that is characterized by immune system abnormalities, vascular damage, and extensive fibrosis of the skin and visceral organs. alpha 2-antiplasmin is known to be the main plasmin inhibitor and has various functions such as cell differentiation and cytokine production, as well as the regulation of the maintenance of the immune system, endothelial homeostasis, and extracellular matrix metabolism. The expression of alpha 2-antiplasmin is elevated in dermal fibroblasts from systemic sclerosis patients, and the blockade of alpha 2-antiplasmin suppresses fibrosis progression and vascular dysfunction in systemic sclerosis model mice. alpha 2-antiplasmin may have promise as a potential therapeutic target for systemic sclerosis. This review considers the role of alpha 2-antiplasmin in the progression of systemic sclerosis.